Technology Appraisal Committee Meeting (Committee D)

Minutes: Confirmed

Date and Time: Wednesday 23 March 2016, 10:06-15:37

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:
1. Professor Gary McVeigh, Chair Present for all notes
2. Dr Lindsay Smith, Vice Chair Present for all notes
3. Dr Aomesh Bhatt Present for all notes
4. Dr Andrew Black Present for all notes
5. Professor David Bowen Present for all notes
6. Dr Ian Campbell Present for all notes
7. Dr Ian Davidson Present for all notes
8. Mrs Susan Dutton Present for all notes
9. Dr Alexander Dyker Present for all notes
10. Mrs Gillian Ells Present for all notes
11. Professor Paula Ghaneh Present for all notes
12. Dr Susan Griffin Present for all notes
13. Mr Malcolm Oswald Present for all notes
14. Dr Mohit Sharma Present for all notes

In attendance:

Dr Anthony Bewley Clinical expert nominated by AbbVie Present for notes 19 to 27
Meindert Boysen Programme Director, National Institute for Health and Care Excellence Present for notes 01 to 18
Tara Burton Patient Expert nominated by the Hidradenitis Trust Present for noted 19 to 27
Dr Raffaele Califano Clinical expert nominated by Eli Lilly Present for notes 06 to 15
Martin Connock ERG representative, Warwick Evidence Present for notes 01 to 15
Ewen Cummins ERG representative, Warwick Evidence Present for notes 01 to 15
Danielle Conroy Administrator, National Present for all notes
<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Present for notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Sally Doss</td>
<td>Technical Adviser, National Institute for Health and Clinical Excellence</td>
<td>19 to 30</td>
</tr>
<tr>
<td>Dr Jesme Fox</td>
<td>Patient expert nominated by Roy Castle Lung Cancer Foundation</td>
<td>06 to 15</td>
</tr>
<tr>
<td>Caroline Hall</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>01 to 18</td>
</tr>
<tr>
<td>Ceri Harris</td>
<td>Patient expert nominated by Hidradenitis Trust</td>
<td>19 to 27</td>
</tr>
<tr>
<td>Tom Haswell</td>
<td>Patient expert nominated by Independent Cancer Patients’ Voice</td>
<td>06 to 15</td>
</tr>
<tr>
<td>Dr John Ingram</td>
<td>Clinical expert nominated by British Association of Dermatologists</td>
<td>06 to 15</td>
</tr>
<tr>
<td>Helen Knight</td>
<td>Associate Director, National Institute for Health and Care Excellence</td>
<td>All notes</td>
</tr>
<tr>
<td>Sophie Laurenson</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>19 to 30</td>
</tr>
<tr>
<td>Emma Loveman</td>
<td>ERG representative, Warwick Evidence</td>
<td>01 to 15</td>
</tr>
<tr>
<td>Kate Moore</td>
<td>Project Manager, National Institute for Health and Care Excellence</td>
<td>All notes</td>
</tr>
<tr>
<td>John Stevens</td>
<td>ERG representative, School of Health and Related Research</td>
<td>19 to 27</td>
</tr>
<tr>
<td>Dr Yvonne Summers</td>
<td>Clinical expert nominated by Royal College of Physicians</td>
<td>06 to 14</td>
</tr>
<tr>
<td>Paul Tappenden</td>
<td>ERG representative, School of Health and</td>
<td>19 to 27</td>
</tr>
</tbody>
</table>
Related Research

Nwamaka Umeweni  Technical Adviser, National Institute for Health and Clinical Excellence  Present for notes 01 to 18

Non-public observers:

Xavier Armoiry  ERG Observer, Warwick Evidence  Present for notes 01 to 19
Nicola Bodey  Business Analyst, National Institute for Health and Clinical Excellence  Present for notes 01 to 19
Ann Greenwood  Medical Editor, National Institute for Health and Clinical Excellence  Present for notes 01 to 30
Karoline Munro  ERG Observer, Warwick Evidence  Present for notes 01 to 18
Moroulla Whiteley  Business Analyst, National Institute for Health and Clinical Excellence  Present for notes 01 to 30

Notes

Welcome

1. The Vice Chair welcomed all members of the Committee and other attendees present to the meeting. The Vice Chair reviewed the agenda and timescales for the meeting, which included the appraisals of ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer and adalimumab for treating moderate to severe hidradenitis suppurativa.

2. The Vice Chair informed the Committee of the non-public observers at this meeting: Xavier Armoiry, Nicola Bodey, Ann Greenwood, Karoline Munro and Maroulla Whiteley.

3. Apologies were received from Dr Matthew Bradley, Ms Tracey Cole, Professor Simon Dixon, Professor Carol Haigh, Professor John Henderson, Dr Tim Kinnaird, Professor Oluwafemi Oyebode, Dr Paula Parvulescu and Dr Murray Smith.

Any other Business

4. None.
Notes from the last meeting

5. Agreement of the meeting minutes from the committee meeting on 25 February 2016.

Appraisal of ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer

Part 1 – Open session

6. The Vice Chair welcomed the invited experts: Dr Raffaele Califano, Martin Connock, Ewen Cummins, Dr Jesme Fox, Tom Haswell, Emma Loveman and Dr Yvonne Summers to the meeting and they introduced themselves to the Committee.

7. The Vice Chair welcomed company representatives from Eli Lilly to the meeting.

8. The Vice Chair asked all Committee members to declare any relevant interests.

9. Professor Gary McVeigh, Dr Lindsay Smith, Dr Aomesh Bhatt, Dr Andrew Black, Professor David Bowen, Dr Ian Campbell, Dr Ian Davidson, Mrs Susan Dutton, Dr Alexander Dyker, Mrs Gillian Ells, Professor Paula Ghanem, Dr Susan Griffin, Mr Malcolm Oswald and Dr Mohit Sharma all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer.

10. The Vice Chair asked all NICE Staff to declare any relevant interests.

10.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer.

11. The Vice Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.

11.1. Martin Cannock, Ewen Cummins, Dr Jesme Fox, Tom Haswell and Emma Loveman declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer.

11.2. Dr Raffaele Califano declared a personal non-specific financial interest as he has sat on advisory boards and spoke at educational meetings for Eli Lilly; who is the company who produces this technology. This was unrelated but Dr Califano did receive payment for this work.
11.2.1. It was agreed that this declaration would not prevent Dr Califano from participating in this section of the meeting.

11.3. Dr Yvonne Summers declared a personal non-specific financial interest as she has sat on advisory boards for Eli Lilly; who is the company who produces this technology, and Boehringer and Bristol-Myers Squibb who are comparators companies in this appraisal. This was unrelated but Dr Summers did receive payment for this work.  
11.3.1. It was agreed that this declaration would not prevent Dr Summers from participating in this section of the meeting.

12. The Vice Chair introduced the lead team, Dr Ian Campbell, Mrs Susan Dutton and Malcolm Oswald who gave presentations on the clinical effectiveness and cost effectiveness of ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer.

13. The Vice Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

14. The Vice Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

15. The Vice Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

16. Discussion on confidential information continued. This information was supplied by the company.

17. The Committee continued to discuss the clinical and cost effectiveness of ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer.

18. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of adalimumab for treating moderate to severe hidradenitis suppurativa.

Part 1 – Open session

19. The Chair welcomed the invited experts: Dr Anthony Bewley, Tara Burton, Ceri Harris, Dr John Ingram, John Stevens and Paul Tappenden to the meeting and they introduced themselves to the Committee.

20. The Chair welcomed company representatives from AbbVie to the meeting.

21. The Chair asked all Committee members to declare any relevant interests

21.1. Professor Gary McVeigh, Dr Lindsay Smith, Dr Aomesh Bhatt, Dr Andrew Black, Professor David Bowen, Dr Ian Campbell, Dr Ian Davidson, Mrs Susan Dutton, Dr Alexander Dyker, Mrs Gillian Ells,
Professor Paula Ghaneh, Mr Malcolm Oswald and Dr Mohit Sharma all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of adalimumab for treating moderate to severe hidradenitis suppurativa.

21.2. Dr Susan Griffin declared a personal non-specific financial interest as she has sat on an advisory board for Novartis who manufacture a comparator technology. This was unrelated to the technology under consideration but Dr Griffin did receive payment for this work.

9.2.1 It was agreed that this declaration would not prevent Dr Griffin from participating in this section of the meeting.

22. The Chair asked all NICE Staff to declare any relevant interests.

22.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of adalimumab for treating moderate to severe hidradenitis suppurativa.

23. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.

23.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of adalimumab for treating moderate to severe hidradenitis suppurativa.

24. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

25. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

26. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

27. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

**Part 2 – Closed session**

28. Discussion on confidential information continued. This information was supplied by the company.
29. The Committee continued to discuss the clinical and cost effectiveness of adalimumab for treating moderate to severe hidradenitis suppurativa.

29.1. Details of the result of this discussion will be included in the confirmed version of these minutes, which will be published during the week commencing 11 April 2016 after the publication of all decisions taken at this Committee meeting.

30. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

**Date, time and venue of the next meeting**

31. Thursday 28 April 2016 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.